These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37655205)

  • 1. Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced
    Lu S; Zheng X; Sun Y; Huang D; Wu L; Ji Q; Zhou C; Zhou J; Guo Y; Ge M; Ding D; Shao J; Zhang W; Gao M; Cheng Y
    Ther Adv Med Oncol; 2023; 15():17588359231189429. PubMed ID: 37655205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial.
    Raez LE; Kang H; Ohe Y; Khanal M; Han Y; Szymczak S; Barker SS; Gilligan AM
    ESMO Open; 2024 May; 9(5):103444. PubMed ID: 38749381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
    Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V
    Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Zheng X; Ji Q; Sun Y; Ge M; Zhang B; Cheng Y; Lei S; Shi F; Guo Y; Li L; Chen L; Shao J; Zhang W; Gao M
    Ther Adv Med Oncol; 2022; 14():17588359221119318. PubMed ID: 36062046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
    Minchom A; Tan AC; Massarelli E; Subbiah V; Boni V; Robinson B; Wirth LJ; Hess LM; Jen MH; Kherani J; Olek E; McCoach CE
    Oncologist; 2022 Feb; 27(1):22-29. PubMed ID: 34523767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
    Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Lu S; Cheng Y; Huang D; Sun Y; Wu L; Zhou C; Guo Y; Shao J; Zhang W; Zhou J
    Ther Adv Med Oncol; 2022; 14():17588359221105020. PubMed ID: 35923928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Response With Selpercatinib in Patients With
    Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA
    J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065
    [No Abstract]   [Full Text] [Related]  

  • 10. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
    Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
    Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001.
    De Braud F; Deschler-Baier B; Morris JC; Worden F; Han Y; Kiiskinen U; Jen MH; Barker SS; Szymczak S; Gilligan AM
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
    Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
    Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
    [No Abstract]   [Full Text] [Related]  

  • 13. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 14. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
    Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
    JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
    Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
    Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
    Rolfo C; Hess LM; Jen MH; Peterson P; Li X; Liu H; Lai Y; Sugihara T; Kiiskinen U; Vickers A; Summers Y
    ESMO Open; 2022 Aug; 7(4):100551. PubMed ID: 35930972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage
    Goldman JW; Sholl LM; Dacic S; Fishbein MC; Murciano-Goroff YR; Rajaram R; Szymczak S; Szpurka AM; Chao BH; Drilon A
    Front Oncol; 2023; 13():1178313. PubMed ID: 37274265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.